



# WHO recommendation on **Umbilical vein injection of oxytocin for the treatment of retained placenta**



World Health  
Organization

human  
reproduction  
programme **hrp.**  
research for impact  
UNDP · UNFPA · UNICEF · WHO · WORLD BANK



WHO recommendation on  
**Umbilical vein injection of oxytocin for  
the treatment of retained placenta**

WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta

ISBN 978-92-4-001394-0 (electronic version)

ISBN 978-92-4-001395-7 (print version)

© **World Health Organization 2020**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# Contents

Acknowledgements	v
Acronyms and abbreviations	vi
Executive summary	vii
Introduction	vii
Target audience	vii
Guideline development methods	vii
Recommendation	viii
1. Introduction	1
1.1 Background	1
1.2 Rationale and objectives	1
1.3 Target audience	2
1.4 Scope of the recommendation	2
1.5 Persons affected by the recommendation	2
2. Methods	3
2.1 Executive Guideline Steering Group (GSG)	3
2.2 WHO Steering Group	3
2.3 Guideline Development Group (GDG)	3
2.4 Evidence Synthesis Group (ESG)	4
2.5 External partners and observers	4
2.6 External Review Group (ERG)	4
2.7 Identification of priority questions and outcomes	4
2.8 Evidence identification and retrieval	5
2.9 Certainty assessment and grading of the evidence	6
2.10 Formulation of the recommendation	7
2.11 Management of declarations of interests	8
2.12 Decision-making during the GDG meeting	9
2.13 Document preparation	9
2.14 Peer review	9
3. Recommendation and supporting evidence	10
4. Dissemination, adaptation and implementation of the recommendation	11
4.1 Recommendation dissemination	11
4.2 Adaptation	11
4.3 Implementation research considerations	12
5. Research implications	12
6. Applicability issues	13
6.1 Anticipated impact on the organization of care and resources	13
6.2 Monitoring and evaluating guideline implementation	13
7. Updating the recommendation	13
8. References	14

Annex 1.	External experts and who staff involved in the preparation of the recommendation	16
Annex 2.	Priority outcomes used in decision-making	19
Annex 3.	Summary and management of declared interests from GDG members	20
Annex 4.	Evidence to Decision frameworks	22
4.1	Umbilical vein injection of oxytocin solution compared to expectant management	22
4.2	Umbilical vein injection of oxytocin compared to other umbilical vein injection regimens	35

# Acknowledgements

The World Health Organization (WHO) Department of Sexual and Reproductive Health and Research and Department of Maternal, Newborn, Child and Adolescent Health and Ageing gratefully acknowledge the contributions of many individuals and organizations to the updating of this recommendation. Work on this update was coordinated by Fernando Althabe, Tina Lavin, Olufemi Oladapo, Joshua Vogel and Mariana Widmer of the Department of Sexual and Reproductive Health and Research.

WHO extends its sincere thanks to Oluwarotimi Ireti Akinola, Brendan Carvalho, Melania Amorim, Catherine Deneux-Tharaux, Tippawan Liabsuetrakul, Martin Meremikwu, Suellen Miller, Mari Nagai, Hayfaa Wahabi, Dilys Walker and Andrew Weeks who served as members of the Guideline Development Group (GDG), and to Ashraf Nabhan (Chair) for leading the meeting. We also thank Christine East, Gill Gyte, Justus Hofmeyr, Syeda Batool Mazhar, Enrique Oyarzun and Qian Xu, who were members of the External Review Group (ERG). WHO also gratefully acknowledges the contribution of the members of the Executive Guideline Steering Group (GSG).

Edgardo Abalos, Anna Cuthbert, Virginia Diaz, Kenneth Finlayson, Leanne Jones, Frances Kellie and Myfanwy Williams reviewed the scientific evidence, prepared the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tables and drafted the narrative summary of the evidence. Fernando Althabe, Olufemi Oladapo, Joshua Vogel and Mariana Widmer revised the narrative summaries and double-checked the corresponding GRADE tables and prepared the Evidence to Decision (EtD) frameworks. The ERG peer reviewed the final document prior to executive clearance by WHO and publication.

We acknowledge the various organizations that were represented by observers, including Deborah Armbruster (United States Agency for International Development [USAID]), Ingela Wiklund (International Confederation of Midwives [ICM]) and Carlos Fuchtnr (International Federation of Gynecology and Obstetrics [FIGO]). We also appreciate the contributions of staff at the WHO regional offices, including Nino Berdzuli, Bremen De Mucio, Hayfa Elamin, Chandani Anoma Jayathilaka, Ramez Khairi Mahaini, Howard Sobel and Claudio Sosa.

WHO acknowledges the financial support for this work received from USAID, the UNDP–UNFPA–UNICEF–WHO–World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP) and the Department of Sexual and Reproductive Health and Research. WHO emphasizes that donors do not participate in any decision related to the guideline development process, including the composition of research questions, membership of the guideline development groups, conducting and interpretation of systematic reviews, or formulation of the recommendations. The views of the funding bodies have not influenced the content of this recommendation.

## Acronyms and abbreviations

CerQUAL	Confidence in the Evidence from Reviews of Qualitative Research
DOI	declaration of interest
ERG	External Review Group
ESG	Evidence Synthesis Group
EtD	Evidence to Decision
FIGO	International Federation of Gynecology and Obstetrics
GDG	Guideline Development Group
GRADE	Grading of Recommendations Assessment, Development and Evaluation
GSG	Guideline Steering Group
HRP	UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction
ICM	International Confederation of Midwives
IU	international units
MPH-GDG	WHO Maternal and Perinatal Health Guideline Development Group
PICO	population (P), intervention (I), comparator (C), outcome (O)
PPH	postpartum haemorrhage
SDG	Sustainable Development Goal
UNDP	United Nations Development Programme
UNFPA	United Nations Population Fund
UNICEF	United Nations Children's Fund
USAID	United States Agency for International Development
UVI	umbilical vein injection
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_24286](https://www.yunbaogao.cn/report/index/report?reportId=5_24286)

